VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted…

Source

Previous articleSilo Pharma Expands License Agreement and Patent Portfolio
Next articleAlgernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis